ClinicalTrials.Veeva

Menu

Natural History in Children Up to 16 Years with Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes (Otoconex)

S

Sensorion

Status

Enrolling

Conditions

DFNB1A
GJB2 Gene Mutation
DFNB9
OTOF Gene Mutation
AUNB1
Sensorineural Hearing Loss, Bilateral
Congenital Deafness

Treatments

Other: Quality of Life Questionnaires
Other: Pure Tone Audiometry Assessment

Study type

Observational

Funder types

Industry

Identifiers

NCT05402813
SENS-NH01

Details and patient eligibility

About

The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 16 years of age.

Full description

The study aims to:

  • better describe the prevalence of cases of DFNB1A and DFNB9, including the type of mutations, and to assess the clinical course of the disease in children up to 16 years of age who have a mild to profound deafness.
  • better understand the audiological and genetic characteristics of the participants with congenital versus evolutive DFNB1A and DFNB9 deafness.

Enrollment

180 estimated patients

Sex

All

Ages

Under 16 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

Participants meeting all the following main inclusion criteria will be eligible to participate in the study:

  • Aged ≤ 16 years on the date of signed informed consent for cohort 1 and ≤ 10 years for cohort 2;
  • With a diagnosis of non-syndromic, bilateral, mild to profound, sensorineural hearing loss (according to the American Speech Language-Hearing Association);
  • With documented genotyping results showing mutation(s) in GJB2 or OTOF genes;
  • Written informed consent as required by local regulations.
  • Either without Cochlear Implant, or with unilateral or bilateral Cochlear Implant(s)

Exclusion Criteria:

Participants presenting with any of the following main exclusion criteria will not be included in the study

  • Other type of deafness, such as unilateral deafness, persistent conductive deafness, malformation syndrome, syndromic deafness, known familial deafness linked to mutations in other genes than OTOF or GJB2;
  • Documented genotyping results showing pathogenic mutation(s) in other gene(s) than GJB2 or OTOF genes in the tested panel;
  • Unable and/or unwilling to comply with all the protocol requirements and/or study procedures.

Trial design

180 participants in 3 patient groups

Cohort 1a
Description:
Patients without Cochlear Implant, with or without Hearing Aid(s) at study entry
Treatment:
Other: Pure Tone Audiometry Assessment
Other: Quality of Life Questionnaires
Cohort 1b
Description:
Patients receiving unilateral or bilateral Cochlear Implant(s) during the study period, after study entry
Treatment:
Other: Pure Tone Audiometry Assessment
Other: Quality of Life Questionnaires
Cohort 2
Description:
Patients with Cochlear Implant(s) (unilateral or bilateral) at study entry
Treatment:
Other: Pure Tone Audiometry Assessment
Other: Quality of Life Questionnaires

Trial contacts and locations

1

Loading...

Central trial contact

Lionel HOVSEPIAN, MD; Géraldine HONNET, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems